Resistance Exercise and Supraphysiologic Androgen Therapy in Eugonadal Men With HIV-Related Weight Loss
A Randomized Controlled Trial

Alison Strawford, PhD
Theresa Barbieri
Marta Van Loan, PhD
Elizabeth Parks, PhD
Don Catlin, MD
Norman Barton, MD, PhD
Richard Neese, PhD
Mark Christiansen, MD
Janet King, RD, PhD
Marc K. Hellerstein, MD, PhD

The primary aim of therapy in wasting syndromes is to restore lean tissue.1,2 The use of alimentation or appetite stimulants in wasting due to human immunodeficiency virus (HIV) has, however, resulted in fat deposition with little lean tissue gains.3-6 Administration of HIV-protease inhibitors to patients with acquired immunodeficiency syndrome (AIDS) also results in weight gain, but most of the weight gained is body fat.7-10 Alterations in the metabolic or endocrine milieu, inadequate exercise, or other factors may be responsible for disproportionate fat vs lean body mass (LBM) gains in HIV infection. Recombinant growth hormone (rGH)11-14 and androgen replacement therapy in men with low or borderline low serum testosterone concentrations15,16 are effective in restoring LBM in men with HIV infection.

Context Repletion of lean body mass (LBM) that patients lose in human immunodeficiency virus (HIV) infection has proved difficult. In healthy, HIV-seronegative men, synergy between progressive resistance exercise (PRE) and very high-dose testosterone therapy has been reported for gains in LBM and muscle strength.

Objective To determine whether a moderately supraphysiologic androgen regimen, including an anabolic steroid, would improve LBM and strength gains of PRE in HIV-infected men with prior weight loss and whether protease inhibitor antiretroviral therapy prevents lean tissue anabolism.

Design Double-blind, randomized, placebo-controlled trial; post hoc analysis for effect of HIV-protease inhibitor therapy conducted from January to October 1997.

Setting Referral center in San Francisco, Calif.

Patients Volunteer sample of 24 eugonadal men with HIV-associated weight loss (mean, 9% body weight loss), recruited from an AIDS clinic and by referral and by advertisement.

Intervention For 8 weeks, all subjects received supervised PRE with physiologic intramuscular testosterone replacement (100 mg/wk) to suppress endogenous testosterone production. Randomization was between an anabolic steroid, oxandrolone, 20 mg/d, and placebo.

Main Outcome Measures Lean body mass, nitrogen balance (10-day metabolic ward measurements), body weight, muscle strength, and androgen status.

Results Twenty-two subjects completed the study (11 per group). Both groups showed significant nitrogen retention and increases in LBM, weight, and strength. The mean (SD) gains were significantly greater in the oxandrolone group than in the placebo group (5.6 [2.1] vs 3.8 [1.8] g of nitrogen per day \( P = .05 \); 6.9 [1.7] vs 3.8 [2.9] kg of LBM \( P = .005 \); greater strength gains for various upper and lower body muscle groups by maximum weight lifted \( P = .02-.05 \) and dynamometry \( P = .01 -.05 \)). The mean (SD) high-density lipoprotein cholesterol level declined 0.25 (0.14) mmol/L (9.8 [5.4] mg/dL) significantly in the oxandrolone group (\( P < .001 \) compared with placebo). Results were similar whether or not patients were taking protease inhibitors. One subject in the oxandrolone group discontinued the study because of elevated liver function test results.

Conclusions A moderately supraphysiologic androgen regimen that included an anabolic steroid, oxandrolone, substantially increased the lean tissue accrual and strength gains from PRE, compared with physiologic testosterone replacement alone, in eugonadal men with HIV-associated weight loss. Protease inhibitors did not prevent lean tissue anabolism.

JAMA. 1999;281:1282-1290 www.jama.com

See also pp 1275 and 1326.

©1999 American Medical Association. All rights reserved.
The high cost of rGH has limited its use in clinical practice; however, many men with HIV-related weight loss are eugonadal. The use of androgens has not proved effective in the latter group. The optimal strategy for increasing LBM in eugonadal men with HIV-associated weight loss remains uncertain.17

Bhasin et al18 performed an important study documenting the interaction between progressive resistance exercise (PRE) and very high intramuscular dosages of testosterone (600 mg/wk, or 6 times the usual replacement dosage) in healthy, eugonadal men. The combined intervention resulted in significantly greater increases in LBM, muscle size, and strength than either intervention alone. However, the long-term safety and behavioral consequences of testosterone at dosages as high as 600 mg/wk are unknown.

Based on these results in healthy men,18 we performed a randomized, placebo-controlled trial among men with HIV infection. The prospectively defined hypotheses were, first, that a supra-physiologic androgen regimen would increase the LBM and strength gains from PRE in eugonadal men with HIV-associated weight loss and, second, that this interaction would not require extremely high doses of androgens. A subgroup analysis was also included addressing whether protease inhibitor antiretroviral therapy prevents lean tissue anabolic response in HIV-infected men.

**METHODS**

**Experimental Design**

The design was a prospective, randomized, placebo-controlled trial among men with HIV infection. The prospectively defined hypotheses were, first, that a supra-physiologic androgen regimen would increase the LBM and strength gains from PRE in eugonadal men with HIV-associated weight loss and, second, that this interaction would not require extremely high doses of androgens. A subgroup analysis was also included addressing whether protease inhibitor antiretroviral therapy prevents lean tissue anabolic response in HIV-infected men.

<table>
<thead>
<tr>
<th>Patients Registered: 24</th>
<th>Randomized: 24</th>
</tr>
</thead>
<tbody>
<tr>
<td>Received PRE, Replacement T, and Oxandrolone Intervention as Allocated: 11</td>
<td>Did Not Receive Intervention as Allocated: 1</td>
</tr>
<tr>
<td>Noncompliant With Collections During Baseline Period</td>
<td></td>
</tr>
<tr>
<td>Followed Up Through Primary and Secondary Outcomes: 11</td>
<td>Followed Up Through All Primary and Secondary Outcomes: 11</td>
</tr>
<tr>
<td>Withdrawn: 0</td>
<td>Withdrawn: 1 Increased LFTs, Week 5</td>
</tr>
<tr>
<td>Completed Trial: 11</td>
<td>Completed Trial: 11</td>
</tr>
</tbody>
</table>

T indicates testosterone enanthate, 100 mg intramuscularly per week; PRE, progressive resistance exercise; and LFT, liver function test result.

**Figure 1.** Progress of Patients Through Randomized Controlled Trial

**Inclusion Criteria.** Patients were included if they (1) were HIV-seropositive; (2) had experienced at least a 5% weight loss during the preceding 2 years; (3) were clinically stable with no active opportunistic infections and weight stable during the preceding 3 months; (4) were eugonadal (serum total testosterone concentration of 7.8-31.2 nmol/L [225-900 ng/dL]); (5) had maintained a stable antiretroviral regimen for at least 3 months; (6) were not currently or previously participating in PRE or aerobic exercise; and (7) could comply with protocol and give informed consent.

**Exclusion Criteria.** Patients were excluded if they had (1) used testosterone or other androgens in the 3 months preceding the study; (2) used medications or dietary supplements known to alter nutritional status including marniol, megestrol acetate, rGH, thalidomide, pentoxifylline, glucocorticoids, or dehydroepiandrosterone in the 3 preceding months; (3) used investigational agents; (4) had severe diarrhea...
(≥3 loose bowel movements per day), chewing or swallowing difficulties, oropharyngeal pain, or inadequate access to food; and (5) had comorbid medical conditions or abnormalities in screening laboratory test results (blood cell count, chemistry profile).

Thirteen of 24 subjects were taking HIV-protease inhibitor antiretroviral agents in combination with nucleoside and/or nonnucleoside reverse transcriptase inhibitors. Other patient characteristics are shown in Table 1. There were no significant differences between assignment groups for any potential prognostic variables (eg, age, weight, prior weight loss, CD4 cell counts, viral load, serum testosterone levels).

**Metabolic Ward Protocol**

Subjects were confined to the MRU of the Western Human Nutrition Research Center in San Francisco for both 10-day inpatient periods. Energy requirements were estimated using the Harris-Benedict equation with a physical activity level of 1.6.22 Food was provided to match these requirements. Meals were under strict supervision and subjects were required to eat all food provided. Food not eaten was presented at the next meal. During the baseline MRU study, exercise level was sustained through 2 chaperoned walks of 1 km daily. No other exercise was permitted. Weight remained stable to within 2% of starting weight, or dietary alterations were made. For the follow-up MRU admission, the energy requirements were calculated based on readmission weight; food was adjusted during the first 4 days in response to reports of hunger (increments of 418 kJ/d).

During the free-living periods, subjects returned to the study site weekly to receive medication and testosterone injections.

**Exercise Protocol.** The major muscle groups were worked according to a defined protocol individually tailored to each subject’s exercise capacity, based on the 1-repetition maximum (1-RM) measured at baseline.23 Each subject was assigned to a personal trainer who was present at every exercise session. Three exercise trainers participated in the study. The protocol involved three, 1-hour training sessions of resistance exercise per week on nonconsecutive days, alternating between upper and lower body workouts, consisting of 6 upper body exercises and 3 lower-body exercises performed on standard weight-stack isotonic exercise equipment. Three sets of each exercise were performed during a session; each set consisted of 10 repetitions of the exercise at approximately 80% of the subject’s 1-RM. Reassessment of 1-RM was performed at week 4, and the weights were adjusted accordingly. All subjects were able to progress appropriately during the study. No subjects complained about the exercise intensity or dropped out because the exercise was too difficult.

**Nitrogen Balance.** Twenty-four-hour urine and stool collections were carried out each day in the MRU. Nitrogen balance assessment began on the fourth day of each 10-day inpatient phase to allow initial equilibration.

Total urinary nitrogen was analyzed by combustion24 (LECO nitrogen determinator, FP-428 Corp., St Joseph, Mich). Daily urinary creatinine levels were analyzed by spectrophotometric assay (Roche Diagnostic Systems, Somerville, NJ). Stool aliquots were homogenized, lyophilized, crushed, dried, and analyzed for nitrogen content using the LECO analyzer. The SD of repeated measurements of 24-hour nitrogen output in this MRU is less than 0.5 g/d (M.V.L., J.K. unpublished data, April 1997).

Diet composition for both MRU admissions was the same. The mean (SD) protein intake was 1.47 (0.0) g/kg per day (16.1% [0.4%] of dietary energy); 53.4% (0.8%) of dietary intake was from carbohydrate, and 30.7% (0.3%) from fat. The nitrogen content of the diet was verified by combustion. This protein intake is within the range of recommended dietary intake for wasted patients and is the same as we have used previously.15

**Stable Isotope/Mass Spectrometric Studies of de Novo Lipogenesis.** De novo lipogenesis was measured by mass isotopomer distribution analysis.26-28 A constant intravenous infusion of sodium [1-13C]acetate (99% atom enriched, Isotec Inc, Miamisburg, Ohio) at 5.2 nmol/h was performed from 2 AM to 6 PM. Subjects fasted from 8 PM until 9 AM, then ate ad libitum.

Very low-density lipoprotein was isolated from plasma by ultracentrifugation and transesterified for analysis by gas chromatography-mass spectrometry.26 The isotopic enrichment of the intrahepatic acetyl-coenzyme A precursor pool and the contribution from de novo lipogenesis to very low-density lipoprotein palmitate were calculated by mass isotopomer distribution analysis.26,27

**Weight, Height, and Body Composition.** Each morning before breakfast subjects were weighed. Body composition was measured by dual-energy x-
ray absorptiometry (DEXA; Model DPX, Lunar, Madison, Wis). The reproducibility of DEXA for repeated measurements of body composition in the same individual is better than 0.5% (M.V.L., unpublished data, May 1997).

**Resting Energy Expenditure (REE).** Resting energy expenditure was measured by indirect calorimetry using a Deltratrac metabolic monitor (SensorMedics, Yorba Linda, Calif) in the canopy mode for 30 minutes shortly after awakening.

**Muscle Strength Testing.** One-Repetition Maximum Testing. One-repetition maximum testing was carried out with the same exercise equipment used for training. Subjects were given instruction and an opportunity to practice during a trial session.

**Isokinetic Dynamometer Testing.** Strength and endurance were tested by an isokinetic dynamometer (Cybex 6000, Ronkonkoma, NY). Cybex testing was chosen to minimize the effects of neuromuscular learning on measurement outcome since the subjects’ training regimen did not involve the Cybex. Right quadriceps and shoulder muscle strength were assessed by measurement of peak torque (maximum force) during 3 complete repetitions of flexion and extension at a constant angular velocity of 60° per second.

**Serum Gonadal Hormones and Urine Androgen Screening.** Serum gonadal hormone levels were measured by radioimmunoassay (Diagnostic Products Corporation, Los Angeles, Calif). In addition, liquid chromatography–mass spectrometry–mass spectrometry and gas chromatography–mass spectrometry were used to screen urine samples at baseline and week 8 for metabolites of oxandrolone and other widely available testosterone analogs (nandrolone, danazol, stanozolol, methyltestosterone, and fluoxymesterone) as a check of compliance.20,30 The urine testosterone to epitestosterone ratio was also measured as an index of exogenous testosterone administration.20,30

**Quality of Life Measurements.** A portion of the Medical Outcomes Study–HIV Specific Questionnaire31 was administered before and after intervention.

**Blood Chemistries.** Routine blood chemistries, CD4 lymphocyte count, and measurement of serum HIV viral load were carried out by SmithKline-Beecham Laboratories (San Francisco, Calif).

**Open-Label Phase.** A 12-week open-label phase was offered to subjects who completed the placebo-controlled study, during which time testosterone, oxandrolone, and supervised PRE continued to be provided. DEXA scans were performed at the conclusion of the 12 weeks. Reassessment of 1-RM was performed every 4 weeks and the weights were adjusted accordingly.

**Statistical Analysis**

Results are expressed as mean (SD) unless otherwise indicated. Statistical significance was determined using Statview computer software (Abacus Concepts, Berkeley, Calif). A significance level of .05 was used. Unpaired t-tests were used to assess differences between groups at baseline. Repeated measures analysis of variance was used to compare treatment effects over time, with a group factor (treatment) and a trial factor (time). When a significant treatment by time interaction was observed, follow-up comparison was performed using the Tukey Studentized range test at a procedurewise rate of 0.05. Correlations were performed using the Pearson product moment. Analyses were performed on study completers, not on an intention-to-treat basis. The primary outcome measures were nitrogen retention, body composition changes, and muscle strength. Secondary outcome measures were gonadal hormone concentrations, REE, and de novo lipogenesis. The sample size of 12 was calculated to detect a standardized effect size of 0.9 (for effect within each group) and 1.2 (for comparison of effect between groups) for change in LBM, using (1) an estimated SD of between 1.0 and 2.0 kg LBM for the response to effective anabolic therapies in HIV-associated wasting,14,15 and (2) the uncertain biologic significance of LBM changes less than about 1.0 to 1.5 kg in magnitude. Accordingly, n = 12 per group was selected to detect differences in LBM of 2 kg between groups at P < .05, with 80% power.

**RESULTS**

**Subject Completion**

Of the 24 subjects enrolled, 23 completed both inpatient studies, with 22 completing the 8-week study (Figure 1). One subject from the placebo group was disqualified from the study for noncompliance with sample collections during the first inpatient phase. Another subject in the oxandrolone group discontinued at week 5 because of elevated liver function test results. Seventeen of the 22 subjects entered the open-label phase of the study; all 17 completed the 12-week follow-up.

**Nitrogen Balance**

There was a significantly greater cumulative nitrogen retention observed in the oxandrolone group compared with the placebo group (5.6 [2.1] g/d vs 3.8 [1.8] g/d). The change from baseline was significant for both groups (FIGURE 2). All 22 subjects showed an increase in nitrogen retention. There were no differences between the 2
groups for baseline nitrogen balance. Five of the 22 subjects had slightly negative nitrogen balance at baseline, 2 in the placebo group and 3 in the oxandrolone group. Assuming that each gram of retained nitrogen represents 32 g of LBM, the predicted LBM gains are 0.9 (0.4) kg/wk in the placebo group and 1.3 (0.5) kg/wk in the oxandrolone group. Use of protease inhibitors had no effect on nitrogen retention.

**Weight and Body Composition**

There was significant weight gain in both groups (P<.05 for time effect vs baseline); the mean (SD) gains were significantly greater in the oxandrolone group than in the placebo group (6.7 [2.0] kg vs 4.2 [2.8] kg; P=.03) (Figure 3, A). Increases in LBM were significant in both groups relative to baseline (P<.05 for time effect), with a significantly greater increase in the oxandrolone group than in the placebo group (6.9 [1.7] kg vs 3.8 [2.9] kg; P<.005) (Figure 3, B). Regional distribution of accrued LBM by DEXA was not significantly different between the groups. The percentages of total LBM gain by region for those in the oxandrolone group were arms, 20.4% (1.9%); legs, 34.4% (2.3%); and trunk, 45.2% (3.3%). For those in the placebo group, it was arms, 21.2% (8.7%); legs, 21.3% (7.0%); and trunk 57.5% (7.0%).

**Figure 3. Change in Body Weight and Body Composition by Dual-Energy X-ray Absorptiometry at Week 8**

![Figure 3](image_url)

Data are presented as mean (SD). The asterisk indicates significantly different change between the groups by repeated measures analysis of variance (P<.05); dagger, significantly different change from baseline by the Tukey test follow-up procedure (P<.05); and double dagger, significant change from baseline in both groups (P<.05), which is not significantly different between the groups by repeated measures analysis of variance.

**Table 2. Exercise Capacity**

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>Oxandrolone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Repetition, Maximum lbs</td>
<td>Baseline</td>
<td>8 Week</td>
</tr>
<tr>
<td>Chest press</td>
<td>138 (38)</td>
<td>159 (36)</td>
</tr>
<tr>
<td>Shoulder press</td>
<td>76.5 (39)</td>
<td>90.5 (36)</td>
</tr>
<tr>
<td>Biceps pull</td>
<td>41.7 (16)</td>
<td>48.1 (18)</td>
</tr>
<tr>
<td>Triceps push</td>
<td>57.0 (13)</td>
<td>66.3 (15)</td>
</tr>
<tr>
<td>Leg press</td>
<td>186 (75)</td>
<td>232 (80)</td>
</tr>
<tr>
<td>Leg extension</td>
<td>129 (69)</td>
<td>168.8 (76)</td>
</tr>
</tbody>
</table>

*Significantly different change between groups by repeated measures analysis of variance (P<.05).
†Significantly different change from baseline by Tukey test follow-up procedure (P<.05).
‡Significant change from baseline in both groups by repeated measures analysis of variance.
The rate of LBM gain for those in the oxandrolone group was 0.9 (0.2) kg/wk, and for those in the placebo group, it was 0.5 (0.4) kg/wk. There were no differences in weight, LBM, or fat changes between subjects taking and those not taking protease inhibitors. The correlation between the change in nitrogen balance and the change in LBM was significant (*P*<.05, *r*²= 0.46).

A statistically significant decrease in fat occurred in both groups at week 8 (*P* = .005), which was not different between groups (oxandrolone, 1.7 [2.8] kg; placebo, 1.6 [1.9] kg). A significant increase in bone mineral content was also observed in both groups (*P*<.001 for time effect), which was not different between groups (oxandrolone, 105 [101] g; placebo, 80 [83] g).

**Resting Energy Expenditure.** Baseline REE was not significantly different between groups. For the placebo group it was 7414 (874) kJ/d (1772 [209] kcal/d), and for the oxandrolone group it was 6916 (1004) kJ/d (1653 [240] kcal/d), which was 106% (14%) of the values predicted. After the treatment phase, there was a significant increase in REE in the oxandrolone group compared with the placebo group (1213 [1004] kJ/d [290 [240] kcal/d], vs 377 [753] kJ/d [90 [180] kcal/d]; *P* = .03). When expressed per kilogram of LBM, the difference in REE between groups was no longer significant.

**One-Repetition Maximum Testing.** Improvements in strength from baseline were observed for all upper and lower body muscle groups in the oxandrolone and the placebo groups (*P*<.05) (Table 2). The changes in shoulder strength were significantly greater in the oxandrolone group than in the placebo group for measures of both flexion (*P* = .04) and extension (*P* = .01). The changes in lower body (knee) strength were not significantly different between groups. There were no differences between subjects taking and not taking protease inhibitors.

**Cybex Testing**

Significant improvements from baseline were also seen in force of flexion, extension, and total work measured by dynamometer testing of both the shoulder and knee muscles in both groups (Table 2). The changes in shoulder strength were significantly greater in the oxandrolone group than in the placebo group for measures of both flexion (*P* = .04) and extension (*P* = .01). The changes in lower body (knee) strength were not significantly different between groups. There were no differences between subjects taking and not taking protease inhibitors.

**Serum Gonadal Hormone Concentrations and Urine Screening for Androgens.** The endogenous gonadal axis was suppressed in both groups compared with baseline, with significant decreases in luteinizing hormone (*P*<.001) and follicle-stimulating hormone levels (*P*<.001), but there were no differences between groups (Table 3). Serum total testosterone levels were within the normal range and were not significantly different between groups or from baseline. All subjects' urine tested negative for anabolic steroids other than oxandrolone at baseline and during the treatment period. Oxandrolone was undetectable in all subjects at baseline and in the placebo group during treatment but was present in all subjects in the oxandrolone group during treatment. The testosterone to epitestosterone ratio was similar to published normal values (median, 1.1)15 in both groups at baseline (oxandrolone, 1.4 [1.4]; placebo, 1.1 [1.1]), and increased significantly from baseline in both groups (*P*<.05 for time effect). The significantly greater increase in testosterone to epitestosterone ratio in the oxandrolone group compared with the placebo group (44.0 [25.0] vs 16.7 [12.8], after treatment; *P*< .002) (Figure 4) suggests that residual endogenous androgen synthesis in the presence of testosterone replacement alone was more completely suppressed by the addition of oxandrolone.

**Stable Isotope/Mass Spectrometric Measurement of de Novo Lipogenesis.** Baseline de novo lipogenesis was elevated in both groups, compared with
**EXERCISE PLUS ANDROGENS IN HIV WASTING**

**Table 4. Change in Blood Parameters**

<table>
<thead>
<tr>
<th>Measurements</th>
<th>Placebo</th>
<th>Oxandrolone</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4 cell count, ×10^6/L</td>
<td></td>
<td></td>
</tr>
<tr>
<td>After treatment</td>
<td>0.310 (0.260)</td>
<td>0.234 (0.108)</td>
</tr>
<tr>
<td>Change from baseline values</td>
<td>−0.028 (0.087)</td>
<td>0.0 (0.057)</td>
</tr>
<tr>
<td>High-density lipoprotein cholesterol, mmol/L [mg/dL]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>After treatment</td>
<td>0.89 (0.46) [34.2 (17.8)]</td>
<td>0.44 (1.1) [16.9 (4.1)]†</td>
</tr>
<tr>
<td>Change from baseline values</td>
<td>−0.02 (0.11) [−0.7 (4.6)]</td>
<td>−0.25 (0.14) [−9.8 (5.4)]†</td>
</tr>
<tr>
<td>Total cholesterol, mmol/L [mg/dL]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>After treatment</td>
<td>4.5 (1.1) [173 (42)]</td>
<td>4.5 (1.6) [175 (60)]</td>
</tr>
<tr>
<td>Change from baseline values</td>
<td>−0.06 (0.50) [−2.4 (19.4)]</td>
<td>1.1 (0.80) [4.3 (30.9)]</td>
</tr>
</tbody>
</table>

*Data are presented as mean (SD). All patients received testosterone and participated in progressive resistance exercise.*

†Significantly different change from baseline between groups (P < .05).

The LBM gains reported previously in AIDS patients is instructive (Table 5). The LBM gains and nitrogen retention in members of the oxandrolone group in the current study are considerably greater than with previously reported therapies in HIV infection or cancer cachexia. The remarkable increases observed in LBM and strength in the oxandrolone group obviate the need to consider massive doses of androgens or anabolic steroids for the treatment of weight loss in HIV-infected men, in our view.

Moreover, the use of protease inhibitor therapy did not affect the gains in lean tissue or muscle strength, based on our post hoc analysis. This is an important point because weight gain after initiation of protease inhibitor treatment represents predominantly body fat. Although our post hoc analysis must be interpreted with caution, the use of protease inhibitors did not prevent substantial gains in LBM. Finally, it is interesting to compare these results in men with HIV infection and prior weight loss with results previously reported by Bhasin et al using high-dose testosterone with PRE and the long-term to patients, eg, with alcoholic hepatitis. In contrast, the safety and behavioral consequences of extremely high doses of testosterone have not been established.

Several independent measures confirmed that LBM gains represent functional lean tissue. Strength was markedly improved; nitrogen retention was substantial and correlated with accrual of LBM; and REE increased. These complementary findings strengthen the external validity of the conclusion that lean tissue anabolism was significantly improved. Because the precision of measures such as DEXA and nitrogen balance is extremely good, the central issue of interpretation in studies attempting to alter body composition relates more to external validity (ie, biological meaning of measured changes) than to internal validity (ie, precision and accuracy of the measurements).

**Quality of Life Measurements**

No change was observed for overall health or energy/fatigue domains, although there were significant increases in the physical function domain (P = .001 for time effect).

**Blood Chemistries.** There were no significant changes in CD4 cell counts during the study (Table 4). Viral load decreased nonsignificantly in both groups (oxandrolone, 3.9 [4.3] to 3.7 [4.0] log_{10} copies/mL; placebo, 4.9 [5.3] to 4.8 [5.1] log_{10} copies/mL). There was a statistically significant decrease in high-density lipoprotein cholesterol (HDL-C) and increase in the total cholesterol–HDL-C ratio in the oxandrolone group, but there was no change in either parameter in the placebo group (P < .001 between groups).

**Adverse Effects.** Two subjects in the oxandrolone group had elevated liver function test results, which led to 1 subject’s discontinuing medication before the end of the 8-week study. Both of these patients were also receiving protease inhibitors. Mood swings were reported in 8 subjects, 5 in the oxandrolone group and 3 in the placebo group. In the oxandrolone group, 4 subjects experienced anxiety and 1 reported nausea. Finally, 4 subjects, 2 in each group, reported an increase in libido during the study.

**Open-Label Phase.** The group as a whole continued to gain LBM over 12 weeks (1.0 [0.6] kg), with loss of fat (−0.9 [0.6] kg) (P < .05 for both vs pre-open label). When stratified by preceding study arm, subjects who were oxandrolone-naive had significantly greater gains in LBM (1.8 [0.5] kg) than subjects who previously had taken oxandrolone (0.4 [0.6] kg; P < .05).

**COMMENT**

Perhaps the most important finding of this study is that extremely high dosages of androgens were not required for a significant beneficial interaction with PRE in men with HIV-related weight loss. In their study, Bhasin et al gave intramuscular testosterone at 600 mg/wk. We gave a physiologic replacement dosage of intramuscular testosterone (100 mg/wk) plus an oral anabolic steroid, oxandrolone, at a dosage of 20 mg/d, previously shown to be well tolerated for long-term use in humans. There is no simple way to compare relative potencies of different testosterone analogs; our intent was not to establish the androgen dose-response curve for synergy with PRE but to test the efficacy of a dose and form that has been given safely over the long-term to patients, eg, with alcoholic hepatitis. In contrast, the safety and behavioral consequences of extremely high doses of testosterone have not been established.

Several independent measures confirmed that LBM gains represent functional lean tissue. Strength was markedly improved; nitrogen retention was substantial and correlated with accrual of LBM; and REE increased. These complementary findings strengthen the external validity of the conclusion that lean tissue anabolism was significantly improved. Because the precision of measures such as DEXA and nitrogen balance is extremely good, the central issue of interpretation in studies attempting to alter body composition relates more to external validity (ie, biological meaning of measured changes) than to internal validity (ie, precision and accuracy of the measurements).

Comparison of these results with nutritional and anabolic therapies reported previously in AIDS patients is instructive (Table 5). The LBM gains and nitrogen retention in members of the oxandrolone group in the current study are considerably greater than with previously reported therapies in HIV infection or cancer cachexia. The remarkable increases observed in LBM and strength in the oxandrolone group obviate the need to consider massive doses of androgens or anabolic steroids for the treatment of weight loss in HIV-infected men, in our view.

Moreover, the use of protease inhibitor therapy did not affect the gains in lean tissue or muscle strength, based on our post hoc analysis. This is an important point because weight gain after initiation of protease inhibitor treatment represents predominantly body fat. Although our post hoc analysis must be interpreted with caution, the use of protease inhibitors did not prevent substantial gains in LBM. Finally, it is interesting to compare these results in men with HIV infection and prior weight loss with results previously reported by Bhasin et al using high-dose testosterone with PRE and
placebo with PRE in healthy men. We observed a 7-kg LBM increase in the oxandrolone group and 4 kg in the placebo group compared with the report of Bhasin et al\textsuperscript{28} of 6 kg and 2 kg of fat-free mass, respectively, in HIV-seronegative men. Strength improvements were also comparable. (Lean body mass and fat-free mass differ operationally by the mode of measurement [DSEA and underwater weighing, respectively], but gains in either parameter represent metabolically active, nonfat tissue in this setting.)

Certain design features of this study should be noted. We confirmed compliance and excluded exogenous androgenic anabolic steroid use by monitoring urine and blood.\textsuperscript{29,30} The exercise regimens were supervised and strictly controlled. The intervention was blinded to all study participants, including the exercise trainers. Finally, both the placebo and the oxandrolone groups received a physiologic replacement dose of testosterone. This last feature was included for several reasons: (1) to make hormonal status more comparable between treatment groups, (2) to ensure that borderline hypogonadalism\textsuperscript{11,15} was not present in either group; and (3) to avoid the possibility of inducing hypothalamic hypo gonadism secondary to the exercise program, as has been reported in other clinical settings.\textsuperscript{35,36}

The exercise regimen was well tolerated. Although overtraining can suppress immune function,\textsuperscript{37} we found no evidence of worsening immunologic or virologic status (Table 4). We did observe significantly elevated de novo lipogenesis after PRE in both groups. We speculate that this reflects the systemic effects of cytokine release induced by muscle damage,\textsuperscript{38,39} but we have no direct evidence to support this hypothesis. The lipid profile deteriorated in the oxandrolone group (Table 4), including substantially reduced HDL-C concentrations. Other 17a-methylated androgens also reduce HDL-C concentrations.\textsuperscript{40} This effect on plasma lipid levels could be important in HIV-infected patients, in view of lipid abnormalities associated with HIV infection\textsuperscript{12,41} that can be exacerbated by HIV-protease inhibitors.\textsuperscript{7} One subject in the oxandrolone group was forced to discontinue the study because of elevation of liver enzyme levels. Other adverse effects were modest.

The subjects in this study had experienced on average 8% to 9% weight loss and were currently weight stable. Weight loss of more than 5% is associated with reduced survival and higher rates of opportunistic infections.\textsuperscript{42} Moreover, the goal for patients like these is often to increase strength and exercise capacity. Therefore, we believe that it is reasonable to consider HIV-seropositive patients with this degree of weight loss for a regimen similar to that used in our study, even if their weight is currently stable.

This study was not designed to differentiate between the possible anabolic roles played by the components provided to both study groups (eg, the exercise regimen, replacement dosage of testosterone, diet, or personal attention received through participation). The study was designed to address whether the addition of 20 mg/d of oxandrolone improves the anabolic and functional response to a regimen of PRE and physiologic testosterone replacement. These results answer this question definitively but do not reveal which factors were responsible for gains in the placebo group. Grinspoon et al\textsuperscript{16} showed that administration of testosterone at replacement dosages in frankly hypogonadal men with HIV-related weight loss increases LBM; Strawford et al\textsuperscript{12} demonstrated that nandrolone administration in borderline hypogonadal men also increases LBM. Neither of these studies were performed in eugonadal men, however, and neither involved exercise training. It will be important in future studies to assess the independent role of specific components.

In conclusion, the combination of PRE with a moderately supraphysiologic anabolic regimen that included an anabolic steroid, oxandrolone, resulted in significantly greater increases in lean tissue and muscle strength than PRE with physiologic testosterone replacement alone in eugonadal, HIV-infected men with prior weight loss. The use of protease inhibitor therapy did not affect the lean tissue response.

**Table 5. Comparison of Therapeutic Regimens for HIV–Related Weight Loss**

<table>
<thead>
<tr>
<th>Source, y</th>
<th>Nutritional or Anabolic Therapy</th>
<th>Nitrogen Retention, g/d</th>
<th>Rate of Change in Body Composition, kg/wk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Von Roenn et al\textsuperscript{15}, 1994; and Oster et al\textsuperscript{14}, 1994</td>
<td>Megestrol acetate</td>
<td>. . .</td>
<td>0.00-0.15</td>
</tr>
<tr>
<td>Kotter et al\textsuperscript{2}, 1990</td>
<td>Parenteral nutrition</td>
<td>. . .</td>
<td>0</td>
</tr>
<tr>
<td>Mulligan et al\textsuperscript{13}, 1993; and Schambelan et al\textsuperscript{14}, 1996</td>
<td>rGH</td>
<td>4.0</td>
<td>0.25</td>
</tr>
<tr>
<td>Strawford et al\textsuperscript{12}, 1998</td>
<td>Nandrolone decanoate (hypogonadal)\textsuperscript{†}</td>
<td>3.7</td>
<td>0.25</td>
</tr>
<tr>
<td>Current study PRE</td>
<td></td>
<td>3.8</td>
<td>0.48</td>
</tr>
<tr>
<td>Current study PRE and oxandrolone</td>
<td></td>
<td>5.6</td>
<td>0.86</td>
</tr>
</tbody>
</table>

\textsuperscript{*}HIV indicates human immunodeficiency virus; ellipses, information not available; rGH, recombinant human growth hormone; and PRE, progressive resistance exercise. \\
\textsuperscript{†}Lean body mass (LBM) was determined by dual-energy x-ray absorptiometry. \\
\textsuperscript{‡}Hypogonadal indicates treatment of men with borderline levels of testosterone (lowest quartile of testosterone serum levels).

Author Affiliations: Department of Nutritional Sciences, University of California, Berkeley (Drs Strawford, Parks, Neese, Christiansen, and Hellerstein); Division of Endocrinology and Metabolism, Department of Medicine, San Francisco General Hospital, University of California, San Francisco (Drs Hellerstein and Christiansen); Western Human Nutrition Research Center, United States Department of Agriculture, Presidio of San Francisco (Ms Barbieri and Drs Van Loan and King); Human Nutrition Unit, London School of Hygiene and Tropical Medicine, London, England (Dr Strawford); Biotechnology General Corporation, Iselin, NJ (Dr Barton); and Department of Molecular and
EXERCISE PLUS ANDROGENS IN HIV WASTING

Medical Pharmacology, University of California, Los Angeles (Dr Catlin).

Funding/Support: This work was supported in part by grants DK-40995 from the National Institutes of Health, Bethesda, Md, and Bio-Technology General Corporation, Iselin, NJ (Dr Hellerstein), and from a sport

REFERENCES


2. Suttmann U, Ockeng J, Selberg O, Hoogenstraat L, Deicher H, Muller MJ. Incidence and prognostic value of malnutrition and wasting in human immunodefi-


fect of home total parenteral nutrition on body compo-
sition in patients with acquired immunodeficiency syn-

genesis predicts short-term body composition re-
sponse by bioelectrical impedance analysis to oral nu-


6. Oster MH, Enders SH, Samuels ST, et al. Meges-

gram and abstracts of the 5th Conference on Retro-


8. Hengel RL, Geary JAM, Vuchetich MA, et al. Mu-

9. Roth VR, Angel JB, Kravcik S, et al. Development of central fat pad following treatment with HIV-1 pro-

tease. In: Program and abstracts of the 5th Confer-

ence on Retroviruses and Opportunistic Infections, Feb-


11. Dobs AS, Dempsey MA, Landenson PW, et al. En-


creased de novo hepatic lipogenesis in human immu-
nodeficiency virus infection. J Clin Endocrinol Metab. 1993;76:559-565.

bolic effects of recombinant human growth hor-

mone in patients with wasting associated with hu-

man immunodeficiency virus infection. J Clin Endocrinol Metab. 1993;77:956-962.


873-882.

15. Strawford A, Van Loan M, King J, Hellerstein M.

Effects of nandrolone decanoate on nitrogen bal-

ance, lean body mass, metabolic abnormalities and per-
formance in borderline hypogonadal men with HIV-


20:137-147.


ing syndrome: a randomized, double-blind, placebo-


17. Hellerstein MK. Nutritional and endocrine con-


York, NY: Cambridge University Press; 1996:194-

209.


335:1-7.

19. Mendenhall CL, Moritz TE, Roselle GA, et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis. Hepato-


20. Mendenhall CL, Anderson S, Garcia-Pont P, et al. Short-term and long-term survival in patients with al-

coholic hepatitis treated with oxandrolone and pred-


21. Malhotra A, Poon E, Tse WV, Pimlott PJ, Hind-

marsh PC, Brook CG. The effects of oxandrolone on the growth hormone and gonadal axis in boys with constitutional delay of growth and puberty. Clin En-

docrinol. 1993;38:393-398.


23. Kramer WY, Fry AC, Strength testing: develop-

ment and evaluation of methodology. In: Maud PJ, Foster C, eds. Physiological Assessment of Human Fit-


25. Cook JGH. Factors influencing the assay of cre-


1841-1852.

27. Hellerstein MK, Neese R. Mass isotopomer dis-

tribution analysis: a technique for measuring biosyn-


28. Hellerstein MK, Schwarz JM, Neese RA. Regula-


litical chemistry at the games of the XXIllrd Olym-